- Statistically significant and clinically meaningful 2.72 point reduction from baseline and 1.64 point placebo-adjusted (p=<0.0001) reduction in primary endpoint of cholestatic pruritus

- Pre-NDA meeting with the U.S. Food and Drug Administration (FDA) scheduled for summer 2026

- Full results to be presented in late-breaking oral presentation at the EASL International Liver Congress 2026